Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Ad hoc announcement pursuant to Art. 53 LR Q2 sales grew +9% (cc 3 , +7% USD) with core operating income growing +17% (cc, +9% USD) Innovative Medicines (IM) sales grew +9% (cc, +7% USD) and core operating income +20% (cc, +12% USD), with core margin reaching 39.0%, (+340 bps cc) Growth driven by continued strong performance from Entresto, Kesimpta, Pluvicto and Kisqali Sandoz sales grew +8% (cc, +5% USD) and core operating income +6% (cc, -5% USD) Q2 operating income grew +50% (cc, +31% USD) mainly driven by higher sales and lower restructuring charges.

Novartis delivers strong sales growth, robust margin expansion and raises guidance. Announces USD 15 billion share buyback and Board endorses Sandoz spin-off[1],[2]

Novartis (NVS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Novartis (NVS) Might Surprise This Earnings Season

When Novartis (NVS) reports second-quarter 2023 results, investor focus is likely to be on updates related to Sandoz's spin-off besides the top- and bottom-line numbers.

Novartis (NVS) to Report Q2 Earnings: Is a Beat in Store?

Novartis (NVS) faces a setback in the patent litigation with respect to the blockbuster heart disease drug Entresto. Shares decline.

Novartis (NVS) Entresto Patent Faces Setback, Stock Down

The pharmaceutical giant suffered a setback with one of its top-selling drugs. The patent for Entresto was invalidated in a court proceeding.

Why Novartis Stock Slipped on Friday

Ad hoc announcement pursuant to Art. 53 LR U.S. District Court for the District of Delaware ruled the Entresto (sacubitril / valsartan) ‘combination patent' to be invalid Novartis will appeal to the U.S. Court of Appeals for the Federal Circuit to reverse the District Court's ruling No generic Entresto product has received FDA approval as of today Pending a final appeal decision and other ongoing litigation involving multiple patents, any launch once generics receive FDA approval would be ‘at risk' Novartis maintains confidence in short and mid-term growth, maintains 2023 guidance and mid-term outlook Basel, July 07, 2023 — Novartis today announced that the U.S. District Court for the District of Delaware issued a negative decision regarding the validity of a patent covering Entresto and combinations of sacubitril and valsartan, which expires in 2025 with its pediatric exclusivity.

Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto® combination patent; maintains 2023 guidance and mid-term outlook

Chinook Therapeutics

Chinook wasn't looking to sell when Novartis approached. But the deal might be the best bet for patients — and KDNY stockholders.

Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire

Novartis (NVS) signs a deal to divest Xiidra and SAF312 (libvatrep) to Bausch + Lomb for $2.5 billion.

Novartis (NVS) to Divest Xiidra, SAF312 to Streamline Focus

Cellular Biomedicine Group

Merck

Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront

Bausch Health Companies Inc

Eye care company Bausch + Lomb said it would pay $1.75 billion to acquire a portfolio of eye care products from Swiss healthcare giant Novartis.

Bausch + Lomb Buys Novartis Drugs for $1.75 Billion Expanding Eye Care Portfolio

Bausch + Lomb Corp has announced plans to buy dry eye disease treatment Xiidra from Swiss pharma giant Novartis AG (ADR) (NYSE:NVS) in a deal that could be valued as high as $2.5 billion. The two companies reached an agreement Friday for a portion of Novartis' eye medicine portfolio, as Novartis shifts its focus towards the development of new and more profitable drugs.

Bausch + Lomb to acquire dry eye treatment from Novartis in potential $2.5B deal

Bausch + Lomb Corp. BLCO, +7.98% confirmed that it was buying the “dry eye” treatment Xiidra from Novartis AG NVS, +0.90% NOVN, +0.72% in a deal valued at $2.5 billion. Under terms of the deal, Bausch + Lomb will make an upfront payment of $1.75 billion in cash, and could make milestone payments of up to $750 million based based on sales and commercialization thresholds.

Bausch + Lomb to buy ‘dry eye' treatment from Novartis in a $2.5 billion deal

Bausch + Lomb Corp

LAVAL, QC / ACCESSWIRE / June 30, 2023 / Bausch + Lomb Corporation (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (NYSE/TSX:BHC), announced that it has entered into a definitive agreement with Novartis to acquire XIIDRA® (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye. Under the terms of the agreement, Bausch + Lomb, through an affiliate, has agreed to acquire XIIDRA, libvatrep and AcuStream from Novartis for up to $2.5 billion, including an upfront payment of $1.75 billion in cash with potential milestone obligations up to $750 million based on sales thresholds and pipeline commercialization.

Bausch Health's Bausch + Lomb to Acquire Novartis' XIIDRA(R)

Basel, June 30, 2023 — Novartis announced today that it has signed an agreement to divest ‘front of eye' ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued up to USD 2.5 billion, including USD 1.75 billion in upfront cash, plus additional milestone payments. The deal includes Xiidra®, the first approved prescription treatment for the signs and symptoms of dry eye disease, and investigational medicine SAF312 (libvatrep), in development as a first-in-class therapy for chronic ocular surface pain (COSP), as well as the rights for use of the AcuStream delivery device in dry eye indications and OJL332, a second generation TRPV1 antagonist in pre-clinical development.

Novartis signs agreement to divest ‘front of eye' ophthalmology assets in line with focused strategy

Bausch + Lomb Corp said on Friday it would buy Swiss pharma company Novartis' dry-eye drop for $1.75 billion, boosting its drug portfolio for the disease as the market for its treatment grows.

Bausch + Lomb to buy Novartis dry-eye drug for $1.75 billion

Caterpillar

W.W. Grainger

Toll Brothers

Walmart

Toll Brothers (TOL), Walmart (WMT), Caterpillar (CAT), W.W. Grainger (GWW) and Novartis (NVS) could be compelling picks heading into the second half of the year.

5 Dividend Growth Stocks to Buy for Gains in the Second Half

Cosentyx is highly effective for a skin condition known as hidradenitis suppurativa. The new indication could have blockbuster potential for Novartis.

Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions

That value proposition took a huge step forward on Monday when Novartis announced a $3.2 billion acquisition of Seattle-based biotechnology company Chinook Therapeutics. A specialist in the development of precision medicines for chronic kidney diseases, Chinook Therapeutics becomes the latest addition to Novartis' expanding innovative medicines portfolio.

Novartis Stock Screams Value After Chinook Therapeutics Buyout

Chinook Therapeutics (NASDAQ: KDNY ) has been surging all day. Why? KDNY stock surged on news that multinational pharmaceutical giant Novartis (NYSE: NVS ) will acquire the firm, which is known for kidney care and treatment.

KDNY Stock Alert: Why Short Seller Muddy Waters Is Betting Against Chinook

Travere Therapeutics

Vera Therapeutics

In light of a Novartis NVS, -0.94% deal to acquire Chinook Therapeutics Inc. KDNY, +58.09%, which is developing treatments for a rare kidney disease, two other companies focused on the same disease look even more attractive, analysts said Monday.

Novartis deal for Chinook makes kidney-treatment competitors more attractive, analysts say

Novartis (NVS) is looking to strengthen its renal pipeline with the acquisition of Chinook Therapeutics for $3.5 billion, which adds two late-stage medicines in development for rare, severe chronic kidney diseases.

Novartis (NVS) to Buy Chinook for $3.5B to Strengthen Pipeline

Novartis agreed to buy Chinook Therapeutics for up to $3.5 billion.

Chinook Therapeutics Shares Soar on Novartis Purchase

Swiss biopharma giant Novartis announced Monday it plans to buy Seattle-based Chinook Therapeutics for $3.

Novartis to buy Seattle biotech firm Chinook Therapeutics in $3.2B deal

Chinook Therapeutics, Inc stock surged by more than half in early trade after the company said it agreed to a $40 per share buyout offer by Novartis AG (ADR) (NYSE:NVS).  The $3.2 billion offer represents a 67% premium to Chinook's closing price on Friday, May 9, and is 83% higher than the 60-day volume-weighted average price of its shares.

Novartis makes Chinook Therapeutics $3.2B offer

Chinook said it has entered an agreement to be acquired by Novartis for $40 per share in cash, with additional cash contingent on regulatory progress with astrasentan, its kidney disease drug candidate.

News for Novartis Stock (NVS)